The tweet was deleted by the author.
But we saved everything 🙂.
Atossa Therapeutics delivered an oral update on its clinical trial of (Z)-endoxifen during the MDA Clinical and Scientific Conference held on March 11, 2026, in Orlando, Florida.
The presentation focused on the latest advancements in (Z)-endoxifen, a novel therapeutic approach intended for potential applications in cancer treatment. Details from the presentation are available in the company’s recent press release.
The company's update builds on a growing body of research into (Z)-endoxifen's therapeutic potential, reinforcing Atossa's long-term vision for cancer prevention as outlined in its Z-Endoxifen strategy for breast cancer prevention. The ongoing expansion of the platform, with a focus on molecular precision, further reflects progress highlighted in previous coverage of Atossa Therapeutics' advances in oncology and DMD targeting.